We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Arena (ARNA) This Earnings Season?
Read MoreHide Full Article
Arena Pharmaceuticals, Inc. is scheduled to report third-quarter 2017 earnings on Nov 7, after the market closes.
Year to date, Arena’s shares have soared 96% compared with the industry’s 3.9% increase.
Arena’s earnings performance is a mixed bag. While the company surpassed expectations in two of the last four quarters, it missed estimates in the other two. Overall, the company delivered an average positive surprise of 70.15% in the trailing four quarters.
Arena Pharmaceuticals, Inc. Price and EPS Surprise
Last quarter, the company missed expectations with a negative earnings surprise of 13.24%.
Let’s see, how things are shaping up for this announcement.
Factors at Play
The only approved product in Arena’s portfolio is obesity treatment drug, Belviq, which has delivered an unimpressive performance so far. We note that ramping up sales in the U.S. anti-obesity market is challenging due to several factors, including the tendency of health care providers to treat obesity symptoms instead of the disease itself, lesser focus on certain patient types for the treatment and historically, low third-party insurance coverage. The Zacks Consensus Estimate for Belviq is $1.9 million for the third quarter.
Arena has a few candidates in its pipeline on which, we expect an update in the third-quarter conference call. In July, the company announced that a phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension (‘PAH’), met its primary endpoint. This positive data from the trial paves way for an expedited initiation of a phase III program on the candidate.
Other candidates include etrasimod (phase II for ulcerative colitis with data expected in the fourth quarter of 2017) and APD371 (phase II study for treatment of pain associated with Crohn’s disease). Etrasimod has the potential to be developed for additional indications beyond inflammatory bowel disease.
What Our Model Indicates
Our proven model does not conclusively show that Arena will beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But this is not the case here, as you will see below.
Zacks ESP: Arena has an Earnings ESP of 0.00% because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 69 cents.You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Arena currently carries a Zacks Rank #3, which increases the predictive power of the ESP. However, an Earnings ESP of 0.00% makes surprise prediction difficult.
We caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks worth considering as per our model, these have the right combination of elements to beat estimates this quarter:
Agenus Inc. (AGEN - Free Report) is scheduled to release results on Nov 7. The company has an Earnings ESP of +8.11% and carries a Zacks Rank of 2 as well.
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) is expected to release results on Nov 6. The company has an Earnings ESP of +3.20% and carries a Zacks Rank of 3 as well.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Image: Bigstock
What's in the Cards for Arena (ARNA) This Earnings Season?
Arena Pharmaceuticals, Inc. is scheduled to report third-quarter 2017 earnings on Nov 7, after the market closes.
Year to date, Arena’s shares have soared 96% compared with the industry’s 3.9% increase.
Arena’s earnings performance is a mixed bag. While the company surpassed expectations in two of the last four quarters, it missed estimates in the other two. Overall, the company delivered an average positive surprise of 70.15% in the trailing four quarters.
Arena Pharmaceuticals, Inc. Price and EPS Surprise
Arena Pharmaceuticals, Inc. Price and EPS Surprise | Arena Pharmaceuticals, Inc. Quote
Last quarter, the company missed expectations with a negative earnings surprise of 13.24%.
Let’s see, how things are shaping up for this announcement.
Factors at Play
The only approved product in Arena’s portfolio is obesity treatment drug, Belviq, which has delivered an unimpressive performance so far. We note that ramping up sales in the U.S. anti-obesity market is challenging due to several factors, including the tendency of health care providers to treat obesity symptoms instead of the disease itself, lesser focus on certain patient types for the treatment and historically, low third-party insurance coverage. The Zacks Consensus Estimate for Belviq is $1.9 million for the third quarter.
Arena has a few candidates in its pipeline on which, we expect an update in the third-quarter conference call. In July, the company announced that a phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension (‘PAH’), met its primary endpoint. This positive data from the trial paves way for an expedited initiation of a phase III program on the candidate.
Other candidates include etrasimod (phase II for ulcerative colitis with data expected in the fourth quarter of 2017) and APD371 (phase II study for treatment of pain associated with Crohn’s disease). Etrasimod has the potential to be developed for additional indications beyond inflammatory bowel disease.
What Our Model Indicates
Our proven model does not conclusively show that Arena will beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a solid Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But this is not the case here, as you will see below.
Zacks ESP: Arena has an Earnings ESP of 0.00% because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 69 cents.You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Arena currently carries a Zacks Rank #3, which increases the predictive power of the ESP. However, an Earnings ESP of 0.00% makes surprise prediction difficult.
We caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some health care stocks worth considering as per our model, these have the right combination of elements to beat estimates this quarter:
Clovis Oncology, Inc. is scheduled to release results on Nov 1. The company has an Earnings ESP of +2.01% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Agenus Inc. (AGEN - Free Report) is scheduled to release results on Nov 7. The company has an Earnings ESP of +8.11% and carries a Zacks Rank of 2 as well.
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) is expected to release results on Nov 6. The company has an Earnings ESP of +3.20% and carries a Zacks Rank of 3 as well.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>